



# JASCC Seminar 2017 in Washington DC

## Optimal CINV therapy on non-Carboplatin MEC

-Triplet, DEX sparing, CINV risk assessment-



**Date** 2017年6月22日(木) 19:00~20:30

**Venue** Washington Marriott Wardman Park  
"MEZZANINE LEVEL(中2階) : WILSON A-C"  
2660 Woodley Rd NW, Washington, DC 20008 , USA

**Chair** **田村和夫 先生**  
(福岡大学医学部総合医学研究センター)  
**Matti S Aapro, MD**  
(Clinique de Genolier, Switzerland)

- Session**
- 1. Prevention of nausea and vomiting in patients receiving non-carboplatin MEC**  
**Jørn Herrstedt, MD, DMSci**  
(University of Southern Denmark, Denmark)
  - 2. Pros and cons of the antiemetic treatment with steroid - steroid sparing**  
**中島 貴子 先生** (聖マリアンナ医科大学 腫瘍内科)
  - 3. Antiemetic treatment based on CINV risk assessment**  
**Karin Jordan, MD**  
(Heidelberg University Hospital, Germany)

**Discussion**

## Optimal CINV therapy on non-Carboplatin MEC

Co-sponsored by



一般社団法人  
日本がんサポーターシップケア学会/  
Japanese Association of Supportive Care in Cancer



大鵬薬品工業株式会社  
TAIHO PHARMACEUTICAL CO., LTD.